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Introduction {#sec1}
============

Cancer immunotherapy is nowadays a consolidated strategy, and therapeutic cancer vaccines are a matter of vast research ([@bib6]). The use of cancer vaccines is an active, specific immunotherapy strategy to present non-self-antigens to the immune system, eliciting an antitumor immune response and leading to tumor cells\' killing ([@bib18]). Cell surface-exposed carbohydrates deserve special attention, because several cancer cells can be differentiated from normal cells by the presentation on their surface of non-common glycosylation motifs (tumor-associated carbohydrate antigens \[TACAs\]) ([@bib55]). In fact, although poorly immunogenic and usually T cell independent, carbohydrate antigens, if properly presented to the immune system, can be recognized as non-self and induce an effective immune response ([@bib9], [@bib12], [@bib22], [@bib25]). Indeed, it has been reported about some patients with cancer able to induce natural auto-antibodies directed against native TACAs and with an improved survival rate ([@bib32], [@bib39]).

In the last two decades great attention has been caught by the MUC1 antigen, α-Tn (or Tn, [Figure 1](#fig1){ref-type="fig"}). The Tn is a cryptic antigen masked in normal human cells but exposed in more than 90% primary adenocarcinomas, due to the incomplete synthesis of the oligosaccharide portions, which are physiologically O-glycosylated to the MUC1 backbone. Tn antigen has been detected at early tumor stage, and its expression is associated with tumor invasiveness and metastasis ([@bib26]). In breast cancer (BC) a correlation among the high level of Tn antigen expression in the primary tumor, tumor size, and a poor prognosis is known, since 20 years ([@bib47], [@bib52]). Worldwide, BC is the most common cancer in women (20% of all cases). Among the different BC kinds, the triple-negative BC (TNBC) is the most difficult to treat for it is very aggressive, prone to metastasize, and resistant to the current anti-BC therapies ([@bib27]).Figure 1Structure of Tn Antigen, **TnSer**, **TnThr,** and TnThr Mimetic, **1**

Structurally simple, the Tn determinant (α-O-GalNAc, linked to the MUC-1 peptide through a residue of Ser or Thr) has been the TACA selected for the development of fully or semi-synthetic cancer vaccines ([@bib10], [@bib30], [@bib41], [@bib57]). Recently, relevant insights have been reported on the non-equivalence of Ser versus Thr MUC1 O-glycosylation residue (TnSer versus TnThr, [Figure 1](#fig1){ref-type="fig"}) ([@bib24]). Noteworthy, TnThr is rather rigid in solution when compared with the more flexible TnSer; consequently in TnThr the sugar portion assumes a different spatial arrangement compared with TnSer ([@bib38], [@bib7], [@bib36], [@bib37]). This difference is mirrored in their bond state with a lower binding affinity of TnSer with respect to TnThr for anti-MUC1 SM3 antibody. Taking advantage from these findings, non-natural determinants have been proposed to obtain more antigenic structures ([@bib11], [@bib17], [@bib46]). About that, few years ago we proposed a "locked" mimetic of the TnThr antigen, namely, **1** ([Figure 1](#fig1){ref-type="fig"}), which is stable and able to elicit a specific immune response *in vivo* ([@bib42]). In this study, we report on the synthesis, characterization, and immunological evaluation of CRM197 (Cross Reactive Material 197) glycoconjugates presenting residues of mimetic **1**, as candidate vaccine to treat non-responsive TNBC.

CRM197 decorated with only four residues of **1**, named **mime\[4\]CRM,** is able to properly activate human dendritic cells (DCs) and, of note, the administration of **mime\[4\]CRM** to a TNBC animal model not only produced tumor size reduction but also interfered in the lung metastasis\' development. To the best of our knowledge, although specific antibodies or immune checkpoint inhibitors (passive immunotherapy) against TNBC have been approved or are in clinical trial ([@bib19]), no example of cancer vaccine for the active immunotherapy of TNBC is currently approved or under advanced clinical development ([@bib53], [@bib58]). In this panorama, the results herein reported represent a novelty in the non-native TACA-based vaccines research.

Results and Discussion {#sec2}
======================

Synthesis and Characterization of Compounds 2, 3, and **Mime\[4\]CRM** {#sec2.1}
----------------------------------------------------------------------

In the design of glycoconjugate vaccines, important issues shall be taken into account, in particular (1) due to the typical weak binding interactions between lectins (i.e., macrophage galactose lectins \[MGLs\], Dectin-1, or DC-SIGN on DCs) and single glycans, a multivalent presentation of individual carbohydrate antigens linked to carriers (generally immunogenic proteins, peptides or synthetic scaffolds) is assembled to augment the binding interaction and trigger a robust recognition event and (2) to elicit TACA-specific IgG antibodies, vaccine constructs also include Toll-like ligands (Toll-like receptor) ([@bib31], [@bib51], [@bib14]) or a T helper peptide, as internal adjuvant ([@bib41]). The outcome is the assembly of demanding constructs presenting immunodominant protein carriers, which often fail in inducing TACA-specific antibodies, eliciting undesired auto-immunity. In keeping these issues and capitalizing on the encouraging results obtained with TnThr mimetic **1** ([@bib16], [@bib23], [@bib34], [@bib42]), we synthesized the differently activated derivatives **2** and **3**, from **4** as starting material ([Scheme 1](#sch1){ref-type="fig"}), to decorate the clinically validated carrier-adjuvant protein CRM197 under mild conditions. The acetyl derivative **4**, obtained as reported ([@bib3]), was reacted with the mono Boc-protected 1,6-diaminohexane, in the presence of 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate and N-methylmorpholine (NMM), in dimethylformamide (DMF), to afford derivative **5** (85%). The acetyl protecting groups were removed by treating **5** with a solution of ammonia in methanol (**6**, \>90%), whereas the Boc protecting group was cleaved with trifluoroacetic acid. The trifluoroacetic salt **7** was then reacted with *para*-nitrophenyl adipates and NMM in DMF to afford compound **2** (88%, over two steps) ([Scheme 1](#sch1){ref-type="fig"}). The reaction of the activated *para*-nitrophenyl derivative **2** with N-hydroxysuccinimide produced, under mild conditions, the corresponding derivative **3** (40%) ([Scheme 1](#sch1){ref-type="fig"}). More efficiently, compound **3** was also prepared by reacting **7** at room temperature with adipic acid activated as bis-succinimide and NMM, in DMF (51%, over two steps).Scheme 1Synthesis of Activated Derivatives **2** and **3**

CRM197 is a genetically detoxified mutant of diphtheria toxin, obtained by a single amino acid substitution (G52E) ([@bib33]) and characterized by a lower immunogenicity and immunostimulatory effect compared with diphtheria toxin ([@bib8]). Currently, CRM197 is one of the most effective carrier proteins, largely found in human conjugate vaccines, licensed to treat bacterial infections ([@bib40], [@bib44]). This non-toxic protein is a poor B cell-mediated immunogen, also enhancing a carbohydrate-specific plasma response ([@bib40]). In this study, the mimetic **1** was first reacted with a non-immunogenic aliphatic chain ([@bib12]), presenting amidic linkages and ending with a carboxylic residue activated as *para*-nitrophenyl adipate (compound **2** [Scheme 1](#sch1){ref-type="fig"}), or succinimidyl adipate (compound **3**, [Scheme 1](#sch1){ref-type="fig"}), for the subsequent conjugation to the carrier protein. According to published conditions ([@bib50]), CRM197 was treated with **2** or **3,** and, as expected, a different loading of the protein was yielded. Upon conjugation with **2**, up to four synthetic antigens were coupled to CRM197 (**mime\[4\]CRM**), whereas conjugation with **3** allowed to vary the loading of the protein and up to 19 or 34 synthetic glycans were grafted to CRM197 (**mime\[19\]CRM**, **mime\[34\]CRM**) ([Figure 2](#fig2){ref-type="fig"} and [Supplemental Information](#appsec1){ref-type="fn"}, [Data S8--S11](#mmc1){ref-type="supplementary-material"}).Figure 2CRM197 Decorated with 4, 19 and 34 Residues of Mimetic 1 or with Residues of GlucoseCRM197 decorated with 4 residues (**mime\[4\]CRM**), 19 residues (**mime\[19\]CRM**), or 34 residues (**mime\[34\]CRM**) of TnThr mimetic **1,** and CRM197 decorated with glucose residues (**Glc-CRM**, used as control, see [Supplemental Information](#appsec1){ref-type="fn"}, [Data S12](#mmc1){ref-type="supplementary-material"}).

1D ^1^H-nuclear magnetic resonance (NMR) spectra were recorded on non-functionalized CRM197 ([Figure S1](#mmc1){ref-type="supplementary-material"}A), on its glycoconjugates **mime\[4\]CRM** ([Figure S1](#mmc1){ref-type="supplementary-material"}B) and **mime\[19\]CRM** ([Figure S1](#mmc1){ref-type="supplementary-material"}C). Significantly, although CRM197 decorated with four residues preserves its original folded structure, the protein conjugated with 19 synthetic glycans is largely unfolded. The dispersion of the NMR signals in the regions of the amide protons and methyl protons provided the main indicators for the folding state of proteins. In the spectrum of **mime\[4\]CRM**, these resonances are well separated, with some signals in the region between 0.5 and −1 ppm, whereas in **mime\[19\]CRM** the signals have narrow chemical shift dispersion without resonance lines of the protein below 0.5 ppm. On the other hand, small-angle X-ray scattering spectra recorded on **mime\[19\]CRM** sample confirmed that this glycoconjugate is aggregated in solution (see [Figure S2](#mmc1){ref-type="supplementary-material"}).

Molecular Dynamics Simulation on **Mime\[4\]CRM** {#sec2.2}
-------------------------------------------------

We then performed molecular dynamics (MD) simulations on mimetic **1**. These calculations showed clear evidence of the conformational restriction imposed by the additional rings to the mimetic (root-mean-square deviation \[heavy atoms\] = 0.84 Å, [Figure 3](#fig3){ref-type="fig"}A) and highlighted the orientation of the amino acid with respect to the sugar moiety relative to natural TnThr. Being aware that a protruding of the TnThr mimetic residues linked to the protein is required for any immune recognition, as an example, we performed also 0.5-μs MD simulations on **mime\[4\]CRM** in explicit water ([Figure 3](#fig3){ref-type="fig"}B). The four unnatural counterparts were conjugated to the most exposed lysine residues displayed on the surface of the protein. According to these simulations, the tertiary structure of CRM197 is not significantly altered upon the chemical modifications and all TnThr mimetic residues are exposed to the solvent ([Figure 3](#fig3){ref-type="fig"}), which is considered essential for the efficacy of the vaccine.Figure 3Molecular Dinamic Simulation on Mimetic **1**and **mime\[4\]CRM**(A) Representative conformer of **TnThr** (as a diamide derivative) in water solution, together with the structural ensemble derived from 0.5-μs MD simulation of mimetic **1**.(B) Representative snapshot derived from 0.5-μs MD simulations of CRM197 (PDB CRM197: [4AE0](pdb:4AE0){#intref0020}) upon chemical modification with 4 molecules of mimetic **1**. A root-mean-square deviation value of 4.7 ± 1.1 Å (protein backbone), relative to the starting structure, was derived from the MD simulations. CRM197 is shown as ribbons, and the unnatural residues are represented as sticks.

Binding of **Mime\[4\]CRM** to anti-Tn Antibody Tn218 {#sec2.3}
-----------------------------------------------------

The affinity shown by the conjugate **mime\[4\]CRM** to the anti-Tn monoclonal antibody Tn218 ([@bib21], [@bib56]) was determined by SPR (Surface Plasmon Resonance) assays ([Figure 4](#fig4){ref-type="fig"} and [Supplemental Information](#appsec1){ref-type="fn"}). The isolated mimetic **1** exhibited an affinity comparable to that of the natural Tn ([Figure S3](#mmc1){ref-type="supplementary-material"}), with a K~D~ = 0.0160 M and 0.0125 M respectively, whereas the multipresentation of the TnThr mimetic **1** on the surface of CRM197 yielded a K~D~ = 1.15 ×10^−5^ M. This result attested the accessibility of **1** to the antibody and showed a binding improvement by presenting multiple copies of the TnThr mimetic on the surface of the protein ([Figure 4](#fig4){ref-type="fig"}).Figure 4Affinity of Glycoconjugate **mime\[4\]CRM** to the Monoclonal anti-Tn Antibody Tn218(A and B) SPR curves and fit obtained for **mime\[4\]CRM** (A) and isolated mimetic **1** (B) toward monoclonal antibody Tn218 (related to [Figure S3](#mmc1){ref-type="supplementary-material"}).

**Mime\[4\]CRM**-Induced Activation of Human Dendritic Cells {#sec2.4}
------------------------------------------------------------

DCs are central regulators of the adaptive immune response and important actors in elicitation of anti-tumoral responses. MGLs are C-type lectins exclusively expressed by human DCs and activated macrophages. A structural preference of MGLs for terminal GalNAc, including Tn antigen, has been reported ([@bib59], [@bib13]). We thus investigated the potential role of **mime\[4\]CRM** in DCs\' activation and/or maturation, aiming to check the possible immunogenicity of this new vaccine candidate in humans. For that, DCs were differentiated from peripheral blood adherent mononuclear cells (PBMCs) of healthy donors, and the expression of markers CD83 and CD86 after stimulation for 48 h with **mime\[4\]CRM** or controls was checked ([Figure 5](#fig5){ref-type="fig"}). Flow cytometry analysis showed that **mime\[4\]CRM** induced activation and maturation of DCs as demonstrated by the increased expression of CD83 and CD86 markers. In contrast, **Glc-CRM** ([Figure 2](#fig2){ref-type="fig"}) and native TnThr peptide, used as controls, did not (see [Supplemental Information](#appsec1){ref-type="fn"} for details). Although in-depth studies are necessary to confirm a binding interaction of MGLs with TnThr mimetic residues on CRM, these results clearly demonstrated the ability of candidate vaccine to properly activate DCs.Figure 5Evaluation of Human DCs\' ActivationDCs isolated from three healthy donors have been stimulated with **mime\[4\]CRM**, **Glc-CRM,** or native Tn. Glc-CRM and native Tn showed some effect in DCs activation, whereas **mime\[4\]CRM** increased the expression of CD83 and CD86 markers. The data (median ±SD) of CD80, CD83, and CD86 expression on negative control (ctr−), positive control (ctr+, lipopolysaccharide), added with 0.2 mg/mL **mime\[4\]CRM**, with 0.2 mg/mL **Glc-CRM,** or with native Tn (0.05 or 0.2 mg/mL). The difference between **mime\[4\]CRM** treatment and the ctr− was assessed using paired t test; ∗p \< 0.05 (see [Supplemental Information](#appsec1){ref-type="fn"} for detail).

Therapeutic Effect of **Mime\[4\]CRM***In Vivo* by Using Triple-Negative Breast Cancer Transplanted Model {#sec2.5}
---------------------------------------------------------------------------------------------------------

The unique structural features and interesting *in vitro* properties of **mime\[4\]CRM** tethered us to assess its potential anti-tumorigenic action against the challenging TNBCs. Compared with other BC subtypes, TNBCs are more aggressive and prone to generate "*neo*" antigens (including Tn antigen) ([@bib5]). We first verified the overall lack of toxicity of **mime\[4\]CRM** both on the 4T1-Luc cell line, as a cellular model of highly metastatic TNBC ([@bib49]), and in human PBMC exposed to **mime\[4\]CRM** (from 2.3 to 57.5 μg/mL). The glucose conjugate **Glc-CRM** (see [Figure 2](#fig2){ref-type="fig"}) ([@bib43]) or CRM197 alone was also screened as control molecule. **Mime\[4\]CRM** did not show any influence on viability and growth rate on the two cell populations over the observation period ([Figure S5](#mmc1){ref-type="supplementary-material"} and [Supplemental Information](#appsec1){ref-type="fn"}). Similar data have been obtained using the human TNBC cell line MDA-MB231 ([Figure S5](#mmc1){ref-type="supplementary-material"}).

The potential anti-tumorigenic action of **mime\[4\]CRM**, together with the activation of immune cells within the tumor microenvironment, was then evaluated *in vivo* by performing a preclinical study. For this purpose, Tn expressing ([@bib45]) murine 4T1-luc cells (stably expressing Firefly Luciferase gene, see [Supplemental Information](#appsec1){ref-type="fn"}) were implanted into the mammary fat pad gland of immunocompetent syngeneic mouse model (BALB/c mice). Of note, the use of immunocompetent mice properly allows to test the efficacy of immunomodulating compounds. Moreover, recent data showed that wild-type and huMUC1 transgenic mice produced equivalent antitumoral response against a native Tn-containing candidate vaccine ([@bib48]).

After the tumors were established, mice were imaged (Bioluminescence Imaging, BLI, see [Supplemental Information](#appsec1){ref-type="fn"}) at the time of implantation (day 0, T0) and then subcutaneously administered **mime\[4\]CRM** (n = 9) or CRM197 as vehicle for control group (n = 10) every week for 6 weeks ([Figure 6](#fig6){ref-type="fig"}A). As known, high-sensitivity BLI technique adequately allows the study of cell proliferation and migration *in vivo* in specific anatomical sites ([@bib4]).Figure 6Description of the Vaccine Therapy Using **Mime\[4\]CRM** in Transplanted Mammary BC Cells and Their Rate of Proliferation *In Vivo*(A) Representative scheme for the *in vivo* preclinical trial showing 4T1-Luc cells\' injection into the mammary fat pad of n = 19 syngeneic BALB/c mice (at T0), and the weekly subcutaneous administration of **mime\[4\]CRM** (17 mg/kg/weekly) started after 7 days from the time of cell implantation. CRM197 was administered to the control group.(B) Representative BLI images of mice orthotopically transplanted using 4T1-Luc cells implanted (n = 10 control mice, n = 9 treated mice). Mice were imaged every 7 days via *in vivo* BLI to monitor tumor growth from time of implantation (T0) to 28 days after tumor implantation.(C) Quantification of photon emission (p/s) from the region of interest (ROI) in mice treated with **mime\[4\]CRM** or with CRM197 as vehicle. The differences in total flux (photons/seconds, P/S) between the two groups of mice indicated a statistically significant reduction of tumor growth (14 days of treatment: 3.7-fold reduction; 28 days of treatment: 2-fold reduction) as measured by luminescence signal emission from tumorigenic 4T1-LUC cells after 1 week and 3 weeks from tumor injection (∗p \< 0.01, ∗∗p \< 0.05, see [Supplemental Information](#appsec1){ref-type="fn"} for detail). The values are expressed as mean ± SD.(D) Evaluation of drug toxicity using mice body weight in **mime\[4\]CRM**-treated and control mice. The values are expressed as mean ± SD. No significant differences were observed between the two groups (related to [Figure S5](#mmc1){ref-type="supplementary-material"}).

Mice were imaged every 7 days to monitor tumor growth *in vivo* ([Figure 6](#fig6){ref-type="fig"}B and [Supplemental Information](#appsec1){ref-type="fn"} for dissection of the tumor growth from T0 to T42). Mice were then sacrificed at T28, T42, and T54. The obtained results clearly showed that the trend of total flux was significantly reduced after a week (p \< 0.01) and also after 3 weeks (p \< 0.05) of treatment (T14 and T28 post-implantation, respectively) in the group of mice that received **mime\[4\]CRM** compared with the vehicle group ([Figure 6](#fig6){ref-type="fig"}C), thus demonstrating an anti-tumorigenic action *in vivo* of **mime\[4\]CRM**. Remarkably, the reduction in the primary tumor growth between the two groups of mice was still visible after 4 weeks of treatment (i.e., after T28), even though it did not reach statistical significance (data not shown). This was likely due to an untimely interruption of the immunization schedule, along with a substantial tumor burden activation typical of highly aggressive 4T1 cells.

The absence of body and organs\' weight loss ([Figures 6](#fig6){ref-type="fig"}D and [S6](#mmc1){ref-type="supplementary-material"}) in treated mice confirmed that there was no significant acute toxicity induced by **mime\[4\]CRM**, in line with our *in vitro* data.

The immune cells (both lymphoid and myeloid cell populations) infiltrating 4T1 mammary tumor sections from mice (two mice, \#9 and \#19) treated for 3 weeks (T28 post-implantation, [Figure 6](#fig6){ref-type="fig"}A) with CRM197 and **mime\[4\]CRM,** respectively, were investigated by immunofluorescence analyses, by using antibodies directed against CD4 (T lymphocytes), TCR (T lymphocytes), CD11c (DCs), PD1 (immunosuppressive marker mostly expressed on T cells surface), FOXP3 (T regulatory cells \[Tregs\]), CD68 (granulocytes), F4/80 (macrophages), and CD163 (pro-tumorigenic M2 macrophages) ([Figure 7](#fig7){ref-type="fig"}). These markers allowed to investigate the role of **mime\[4\]CRM** in triggering *in vivo* immune cells exerting inhibitory effects or, conversely, promote tumor spread (i.e., CD4+FOXP3+PD1+, immunosuppressive regulatory T lymphocytes; CD68+ F4/80+ CD163+ M2-type macrophages) ([@bib2]).Figure 7Representative Immunofluorescence (IF) Staining of Primary Mammary Tumor Sections from Transplanted Mice Treated with **Mime\[4\]CRM** or with CRM197 as a Vehicle(A--F) IF double staining with (A) T cell receptor (TCR, marker of T cells, red) and CD4 (expressed by both T helper and dendritic cells, green), (B) CD11c (marker of DCs, red) and CD4 (green), (C) programmed cell death protein 1 (PD1, marker of immunosuppressive immune cells, red) and CD4 (green), (D) FOXP3 (marker of regulatory T cells, Tregs, red) and CD4 (green), (E) CD163 (specific marker of M2-polarized macrophages, red) and CD68 (marker of macrophages, green), and (F) CD163 (red) and F4/80 (marker of macrophages, green). DAPI was used to stain the nuclei (blue) in yellow or in pink, the overlays indicating (A) CD4+TCR+ (T lymphocytes), (B) CD4+ CD11c+ (DCs), (C) CD4+ PD1+ (immunosuppressive lymphocytes), (D) CD4+ FOXP3+ (T regulatory cells), and (E and F) CD68+ CD163+ and F4/80+ CD163+ cells (M2 macrophages). Magnification 63×. (a--f) Graphs showing the percentage of positive cells counted in fluorescence staining by using ImageJ software (n = 3 different sections for each tumor were screened within the tumor mass and images and cell positivity were counted). Mice treated with **mime\[4\]CRM**, instead of CRM197, showed a statistically significant increase of T helper lymphocytes (CD4+ TCR+, ∗p \< 0.03; a) and DCs (CD4+ CD11c+, ∗p \< 0.04, b) and a reduction of immunosuppressive lymphocytes (CD4+ PD1+, ∗p \< 0.04, c), T regulatory cells (CD4+FOXP3+, ∗p \< 0.01, d), and M2 tumor-associated macrophages (TAMs; i.e., CD68+ CD163+, ∗p \< 0.003 and F4/80+ CD163+ cells ∗∗p \< 0.007, e and f). The values are expressed as mean ± SD. ∗p \< 0.05; ∗∗p \< 0.007. See [Supplemental Information](#appsec1){ref-type="fn"} for detail.

The data obtained showed increased levels of both T cells (CD4+TCR+) and peripheral DCs expressing CD4+ (CD4+CD11c+) in mice treated with **mime\[4\]CRM** ([Figures 7](#fig7){ref-type="fig"}A and 7B). This suggests that the candidate vaccine is able to modulate the recruitment of both antigen-presenting cells (APCs, i.e., DCs) and T helper CD4+ in the tumor microenvironment of the treated mice. Furthermore, the tumor sections from the same treated mouse also showed a significant reduction of CD4+ T cells expressing the immunosuppressive marker PD1 (PD1+CD4+, [Figure 7](#fig7){ref-type="fig"}C) and the transcriptional factor FOXP3 ([Figure 7](#fig7){ref-type="fig"}D), thus indicating a reduction in the quote of immunosuppressive Tregs in the TNBC microenvironment.

Of interest, in the **mime\[4\]CRM**-treated mouse\'s sections, data also showed a significant reduction in the pro-tumorigenic M2-polarized tumor-associated macrophages (TAMs; i.e., CD68+ CD163+; F4/80+ CD163+; [Figures 7](#fig7){ref-type="fig"}E and 7F). Moreover, the reduction of immunosuppressive T lymphocytes (i.e., PD1+ CD4+) was also shown in the tumor tissues from mice after 42 days from tumor cell implantation (T42), thus suggesting a long-lasting effect of **mime\[4\]CRM** in inhibiting immunosuppressive markers (e.g., PD1) in the tumor microenvironment of TNBC (data not shown). In contrast, the decrease of Tregs (FOXP3+ CD4+) in the same **mime\[4\]CRM**-treated mice was not substantially observed, thus inferring a loss of regulation of conventional T lymphocytes at T42 (results did not reach a statistical significance; data not shown).

Altogether, immunofluorescence staining indicates that **mime\[4\]CRM** vaccine has a clear potential role in modulating the recruitment and phenotype of CD4+ T cells and, as a consequence, on the polarization status of TAMs in the TNBC tumor microenvironment.

As 4T1 cells, used in this study as a cellular model of TNBC, are highly metastatic, the presence of lung metastases was evaluated by performing *in vivo* analyses 42 days after 4T1 TNBC cells were implanted. At T42, our *in vivo* BLI analyses indicated the presence of lung metastases in seven of nine controls and four of eight **mime\[4\]CRM**-treated mice ([Figures 8](#fig8){ref-type="fig"}A and 8B). In contrast, as determined through *ex vivo* BLI imaging, the presence of metastatic foci was detected in eight of nine control mice (seven mice at T42 and one mouse at T54, [Figure 8](#fig8){ref-type="fig"}B), and in four of eight **mime\[4\]CRM**-treated mice (one mouse at T42 and three mice at T54, [Figure 8](#fig8){ref-type="fig"}A). Therefore, although we cannot exclude the presence of lung micro-metastases at T42 in the **mime\[4\]CRM**-treated group of mice because they might not be detectable with the *in vivo* BLI technology, data showed a clear effect of our candidate vaccine in modulating lung metastasis development.Figure 8*In Vivo* and *Ex Vivo* Analyses to Evaluate the Presence of Lung Metastases(A and B) *In vivo* BLI analyses showed only 50% of the **mime\[4\]CRM**-treated mice (four of eight animals) developed lung metastases (A), whereas the presence of metastatic foci was found in seven of nine control mice (i.e.,78%) at T42 (B). *Ex vivo* BLI analyses proved the presence of metastatic foci in eight of nine control mice (seven mice at T42 and one mouse at T54, B lower panel) and in four of eight **mime\[4\]CRM**-treated mice (one mouse at T42 and three mice at T54, A lower panel).

To investigate the immunoediting of mice treated with **mime\[4\]CRM** compared with control mice, the composition of immune cell infiltrate was also analyzed at T54 (i.e., 2 weeks after the last treatment) in the lung ([Figure S6](#mmc1){ref-type="supplementary-material"}) and in BC ([Figure S7](#mmc1){ref-type="supplementary-material"}) tissue, by H&E staining and by immunohistochemistry (two mice and two sections/mouse) using antibodies against CD4, CD8, and FOXP3 markers. In BC, the results showed a statistically significant increase of CD4-positive cells in **mime\[4\]CRM**-treated compared with CRM197-treated mice, whereas no significant differences were seen for CD8 and FOXP3 markers between the two groups (see [Supplemental Information](#appsec1){ref-type="fn"} and [Figure S7](#mmc1){ref-type="supplementary-material"}).

Of note, H&E staining showed a cell infiltrate in the lung of the groups of treated mice ([Figures S6](#mmc1){ref-type="supplementary-material"}B, S6F, and S6G) compared with untreated mice ([Figure S6](#mmc1){ref-type="supplementary-material"}A). However, it is important to note that in CRM197-treated mice the organ presented numerous metastatic cell masses ([Figure S6](#mmc1){ref-type="supplementary-material"}B), whereas **mime\[4\]CRM**-treated mice showed just a single metastatic cell mass ([Figure S6](#mmc1){ref-type="supplementary-material"}G). The composition of the immune cell infiltrate in CRM197-treated mice consisted of several CD4-positive cells diffused in the entire organ, although more numerous in the metastatic masses ([Figure S6](#mmc1){ref-type="supplementary-material"}C), whereas the FOXP3- and CD8-positive cells were confined to the metastatic mass ([Figures S6](#mmc1){ref-type="supplementary-material"}D and S6E). Conversely, in **mime\[4\]CRM**-treated mouse carrying the metastatic mass, there were numerous and dispersed CD4-positive cells ([Figure S6](#mmc1){ref-type="supplementary-material"}H), but very few FOXP3-positive cells limited to the metastatic mass ([Figure S6](#mmc1){ref-type="supplementary-material"}J).

Furthermore, we investigated the potential ability of **mime\[4\]CRM** to decrease Prune-1 protein levels in the treated mice. This protein had previously been reported to be overexpressed in 4T1 cells ([@bib54]) and positively correlated to advanced stage in metastatic BC ([@bib15], [@bib60]). However, immunofluorescence analyses performed on primary tumor sections derived from **mime\[4\]CRM**-treated and vehicle mice did not show differences in Prune-1 levels (data not shown), thus suggesting that the ability of the vaccine **mime\[4\]CRM** to reduce tumor outgrowth does not involve the down-regulation of Prune-1 levels *in vivo*, confirming its action on the modulation of immune infiltrating cells by activating the lymphocytes component.

Cumulative survival analyses between the two groups of mice revealed that seven of nine (77.7%) controls and two of eight treated (25%) mice died at T42, thus indicating a clear trend of therapeutic benefit in **mime\[4\]CRM**-treated versus control mice in the observed period (long rank test p \< 0.083, data not shown).

Anti-TnThr Mimetic 1-Specific Antibody Response Elicited by **mime\[4\]CRM** Immunization {#sec2.6}
-----------------------------------------------------------------------------------------

Results so far described show that mice engrafted with 4T1 cancer cells and immunized with **mime\[4\]CRM** in a therapeutic experimental setting have a reduced tumor burden and, remarkably, impaired distal dissemination. The antibody response introduced by the vaccine was analyzed by measuring the IgG serum titers elicited upon immunization against the glycan portion of **mime\[4\]CRM**. To detect mimetic **1**-specific antibodies, mice sera collected during immunization (T28 and T42) were tested by ELISA on plates coated with the hexapeptide Ala-Pro-Asp-H~2~NSer-Arg-Pro **8** (as negative control, see [Supplemental Information](#appsec1){ref-type="fn"}) or with the glycosylated Ala-Pro-Asp-HNSer(mimetic **1**)-Arg-Pro hexapeptide (**9**, see [Supplemental Information](#appsec1){ref-type="fn"}). Immunization with **mime\[4\]CRM** induced predominantly IgG (almost exclusively IgG1, whereas IgG2a was barely detectable), and to a lower lever IgM (mean titer 1:1,350 and 1:600 respectively), compared with control mice (mean titer 1:600 and 1:100, respectively) (see [Figure S8](#mmc1){ref-type="supplementary-material"}). Sera were then tested for binding on the surface of 4T1 cancer cells by flow cytometry. Notably, mice immunized with **mime\[4\]CRM** elicited antibodies that can better recognize native Tn antigen expressed by BC cells than control mice (approximately 3-fold increase in mean fluorescence intensity, see [Figure S9](#mmc1){ref-type="supplementary-material"}).

A preliminary analysis of serum cytokines revealed a higher level of anti-tumor Th17 cytokines after immunization with **mime\[4\]CRM** ([Figure S10](#mmc1){ref-type="supplementary-material"}). This result was not unexpected, because the ability of Tn glycosylation in inducing interleukin (IL)-17 responses was recently described ([@bib20]). Th17 cells producing IL-17 have been detected in patients with ovarian cancer ([@bib29]) and in mouse tumor models ([@bib28]). Although relevance of IL17+ T lymphocytes in anti-cancer immunity is still controversial, it may contribute to protective tumor immunity by recruiting effector cells to the tumor microenvironment ([@bib1], [@bib29], [@bib35]). In our study, the presence of IL-17 in serum of immunized mice is an additional evidence of **mime\[4\]CRM** immunomodulatory activity on T cells.

Isolation of **Mime\[4\]CRM**-Specific T Cells {#sec2.7}
----------------------------------------------

Capitalizing on these notable results, 12 patients with BC were enrolled to assess the presence of **mime\[4\]CRM**-specific T cells, as in the peripheral blood as in the tumor tissues. In detail, the PBMCs were cultured in the presence of medium alone or with **mime\[4\]CRM**. The presence of **mime\[4\]CRM**-specific T cells was documented in 8 (67%) of the 12 patients. Thus, we isolated **mime\[4\]CRM**-specific T cells, by cloning the tumor-infiltrating cells of the same patients with BC. We obtained a total of 90 T cell clones and 15 (17%) that were specific for **mime\[4\]CRM**. Of note, evaluating the profile of cellular markers of the intra-tumoral **mime\[4\]CRM**-specific T cells, we found that 69% were CD4+, whereas 31% were CD8+ (see [Figure S11](#mmc1){ref-type="supplementary-material"} and [Supplemental Information](#appsec1){ref-type="fn"}). This last evidence demonstrates the ability of **mime\[4\]CRM** to stimulate T cells in patients with BC. A compelling hypothesis is that this might be due to an activation of Tn-specific T cell response spontaneously elicited in cancer tissues.

In conclusion, the results reported in this study demonstrated a therapeutic efficacy of the glycoconjugate **mime\[4\]CRM** in inhibiting tumor growth in mice. The efficacy, likely correlated with a higher frequency of CD4+ T cells and a lower frequency of M2-type macrophages, was assessed in mice inoculated with 4T1-Luc cells and treated with **mime\[4\]CRM**. Specific IgGs were elicited in mice immunized with **mime\[4\]CRM**, which recognized native Tn antigen on BC cells better than sera from control mice. **Mime\[4\]CRM** properly activated human DCs and was able to modulate the recruitment of both APCs and T helper CD4+ in the tumor microenvironment of treated mice. In addition, the isolation from patients with BC of tumor-infiltrating lymphocytes specific for **mime\[4\]CRM** highlighted the intrinsic immunogenicity of the candidate vaccine and its ability to stimulate a specific immune response. These results are unprecedented for a TACA mimetic-based construct. Mice *in vivo* and human *ex vivo* immunogenicity of **mime\[4\]CRM**, characterized by a carbohydrate determinant quite different from that of the native TACA, could be of great interest for the design of structurally innovative cancer vaccines.

Limitations of the Study {#sec2.8}
------------------------

The study provided preclinical data demonstrating the efficacy of **mime\[4\]CRM** as cancer vaccine for TNBC. The predictive value of the proposed TNBC mouse cancer model for **mime\[4\]CRM** as human vaccine deserves further investigations. In particular, efforts should be focused to assess **mime\[4\]CRM** efficiency in the stimulation of the Tn-specific T and B human lymphocytes naturally induced in oncologic patients affected by different Tn-positive cancers.

Resource Availability {#sec2.9}
---------------------

### Lead Contact {#sec2.9.1}

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Cristina Nativi (<cristina.nativi@unifi.it>).

### Materials Availability {#sec2.9.2}

All unique/stable reagents generated in this study are available from the Lead Contact with a completed Materials Transfer Agreement.

Methods {#sec3}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.

Supplemental Information {#appsec2}
========================

Document S1. Transparent Methods, Figures S1--S11, Tables S1--S3, and Data S1--S12
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